Curcumin ameliorates experimental autoimmune encephalomyelitis in a C57BL/6 mouse model.
Animals
Curcumin
/ administration & dosage
Cytokines
/ drug effects
Encephalomyelitis, Autoimmune, Experimental
/ drug therapy
Female
Gene Expression Profiling
/ methods
Gene Expression Regulation
/ drug effects
Glutathione Peroxidase
/ genetics
Injections, Intraperitoneal
Interferon-gamma
/ genetics
Interleukin-17
/ genetics
Interleukin-6
/ genetics
Mice
Mice, Inbred C57BL
Treatment Outcome
Tumor Necrosis Factor-alpha
/ genetics
Glutathione Peroxidase GPX1
EAE
curcumin
multiple sclerosis
Journal
Drug development research
ISSN: 1098-2299
Titre abrégé: Drug Dev Res
Pays: United States
ID NLM: 8204468
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
25
02
2019
revised:
09
04
2019
accepted:
12
04
2019
pubmed:
30
4
2019
medline:
28
1
2020
entrez:
30
4
2019
Statut:
ppublish
Résumé
Multiple sclerosis (MS) is a common inflammatory disease of the central nervous system. Although the exact etiology of the disease is largely unknown, it is identified that cytokines may play an important role in the pathogenesis of MS. In this study, the effects of curcumin has been investigated on the expression levels of selected cytokine coding genes as well as the extent of demyelination in the corpus callosum of C57BL/6 experimental autoimmune encephalomyelitis (EAE) model of MS. Gene expression analyses revealed that treatment with curcumin could lead to a significant reduction in the expression levels of pro-inflammatory cytokine coding genes including IL-6 (p = 0.001), IL-17 (p = 0.001), tumor necrosis factor (TNF)-α (p = 0.008), and interferon (IFN)-γ (p = 0.033) as well as a significant increase in the expression level of transforming growth factor (TGF)-β (p = 0.006) as an anti-inflammatory cytokine. Moreover, the expression of glutathione peroxidase (GPX)-1 gene and the activity of anti-oxidant enzymes were significantly higher (p < 0.001) in curcumin-treated mice. Luxol fast blue staining also confirmed a significant reduction in the extent of demyelination in the curcumin-treated group (p < 0.001). Our results have confirmed that curcumin is an effective therapeutic agent that could ameliorate the severity of EAE.
Substances chimiques
Cytokines
0
IFNG protein, mouse
0
Il17a protein, mouse
0
Interleukin-17
0
Interleukin-6
0
Tnf protein, mouse
0
Tumor Necrosis Factor-alpha
0
interleukin-6, mouse
0
Interferon-gamma
82115-62-6
Glutathione Peroxidase
EC 1.11.1.9
Curcumin
IT942ZTH98
Glutathione Peroxidase GPX1
EC 1.11.1.9
Gpx1 protein, mouse
EC 1.11.1.9
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
629-636Informations de copyright
© 2019 Wiley Periodicals, Inc.